Strikingly, only TRAIL–CDK9i, but neither TRAIL nor CDK9i alone, was highly effective at killing all parental as well as all therapy-resistant melanoma cell lines tested, importantly regardless of the nature of both, their respective oncogenic driver mutations and their respective acquired chemo- or targeted therapy resistance (Fig. 4e-g). The gene discussed is TNFSF10; the disease is melanoma.